Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~19 mi. (Halle, Germany, +93 more cities)

Krankenhaus Martha Maria Halle-Doelau ( Site 0507)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~19 mi. (Halle, Germany, +93 more cities)

Krankenhaus Martha Maria Halle-Doelau ( Site 1314)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

~19 mi. (Halle, Germany, +94 more cities)

Universitäsklinik Halle/Saale

HER2 Negative

Breast Carcinoma

sacituzumab govitecan

chemotherapy, +1 more type

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~19 mi. (Halle, Germany, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants

~19 mi. (Halle, Germany, +71 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

cobolimab, +2 more drugs

chemotherapy, +1 more type

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

~19 mi. (Halle, Germany, +72 more cities)

Universitätsklinikum Halle

del(11)(q10), +27 more biomarkers

Primary Myelofibrosis, +1 more condition

navtemadlin

targeted therapy

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

~19 mi. (Halle, Germany, +57 more cities)

GSK Investigational Site

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

cobolimab, +7 more drugs

chemotherapy, +2 more types

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

~19 mi. (Halle, Germany, +21 more cities)

University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

FLT3 Codon 835 Missense, +2 more biomarkers

Acute Myeloid Leukemia

navtemadlin, +1 more drug

targeted therapy

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~25 mi. (Georgsmarienhütte, Germany, +172 more cities)

Franziskus-Hospital Harderberg

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

~25 mi. (Minden, Germany, +158 more cities)

Johannes Wesling Klinikum Minden ( Site 0908)

Non-Small Cell Lung Carcinoma

olaparib, +4 more drugs

chemotherapy, +3 more types

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~25 mi. (Georgsmarienhütte, Germany, +184 more cities)

Franziskus-Hospital Harderberg

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

~32 mi. (Gütersloh, Germany, +180 more cities)

Exelixis Clinical Site #98

Prostate Adenocarcinoma

atezolizumab, +1 more drug

immunotherapy, +1 more type